Results 41 to 50 of about 13,245 (221)

Explore the Possibility of Early Clinical Diagnosis of Endocrine Ophthalmopathy Based on Eye Symptoms of Hyperthyroidism

open access: yesOftalʹmologiâ, 2016
Purpose: to study the possibility of early clinical diagnosis of endocrine ophthalmopathy based on ocular symptoms of hyperthyroidism. Patients and methods: we analyzed the prevalence of ocular symptoms of hyperthyroidism in 139 patients (278 orbits ...
V. G. Likhvantseva   +3 more
doaj   +1 more source

Diagnostic accuracy of short-time inversion recovery sequence in Graves' ophthalmopathy before and after prednisone treatment [PDF]

open access: yes, 2014
Introduction: In Graves' Ophthalmopathy, it is important to distinguish active inflammatory phase, responsive to immunosuppressive treatment, from fibrotic unresponsive inactive one.
Belfiore, M. P.   +8 more
core   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

open access: yesActa Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset   +13 more
wiley   +1 more source

Graves' disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells [PDF]

open access: yes, 2015
Introduction Patients with autoimmune thyroid disease (AITD) show defects in their immune-regulatory mechanisms. Herein we assessed the expression and function of galectin-1 and galectin-9 (Gal-1, Gal-9) in dendritic cells (DCs) from patients with ...
Ana Ramos-Levi   +37 more
core   +5 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang   +16 more
wiley   +1 more source

Miosite do músculo reto medial como forma atípica de apresentação de linfoma tipo MALT: relato de caso [PDF]

open access: yes, 2014
Here we describe the rare case of a 55-year-old man with medial rectus muscle myositis as an atypical presentation of non-Hodgkin B-cell mucosa-associated lymphoma (MALT).
Dittrich, Mirtha Alicia Ramirez   +4 more
core   +4 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang   +16 more
wiley   +1 more source

Pompe disease and ophthalmopathy: literature review

open access: yesНервно-мышечные болезни, 2015
Large number of ophthalmological problems has been found in patients with glycogenosis type II (Pompe disease, PD). Since enzyme replacement therapy (ERT) has been introduced ophthalmic examination in the routine follow-up gained a special role in ...
Tuy Nga Brignol, J. Andoni Urtizberea
doaj   +1 more source

Inactive Graves' ophthalmopathy and self-esteem [PDF]

open access: yes, 2008
PURPOSE: To assess the self-esteem of Graves' ophthalmopathy patients in the inactive phase. METHODS: Thirty euthyroid patients were evaluated in the inactive phase of disease with age ranging from 26 to 65 years, average of 43 ± 11,0 years, called study
Ferreira, Lydia Masako   +5 more
core   +2 more sources

Application of machine learning in the diagnostic work‐up of telomere biology disorders

open access: yesHemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT We applied supervised and unsupervised machine learning (ML) analyses to a cohort of 140 patients referred to the Hematology Unit of the G. Gaslini Institute from 1989 to 2023 for persistent cytopenia and/or features suggestive of telomere biology disorders (TBDs). Patients were labeled as “TBD” (n = 20, established molecular diagnosis of TBD),
Erika Massaccesi   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy